Does the media refer more to LNTH or PVLA?

In the previous week, Palvella Therapeutics had 3 more articles in the media than Lantheus. MarketBeat recorded 7 mentions for Palvella Therapeutics and 4 mentions for Lantheus. Lantheus' average media sentiment score of 0.54 beat Palvella Therapeutics' score of 0.53 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Palvella Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PVLA or PTGX?

In the previous week, Palvella Therapeutics had 3 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 7 mentions for Palvella Therapeutics and 4 mentions for Protagonist Therapeutics. Palvella Therapeutics' average media sentiment score of 0.53 beat Protagonist Therapeutics' score of 0.43 indicating that Palvella Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palvella Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor RYTM or PVLA?

In the previous week, Palvella Therapeutics had 4 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 7 mentions for Palvella Therapeutics and 3 mentions for Rhythm Pharmaceuticals. Palvella Therapeutics' average media sentiment score of 0.53 beat Rhythm Pharmaceuticals' score of 0.00 indicating that Palvella Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Palvella Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PVLA or SYRE more profitable?

Spyre Therapeutics' return on equity of -42.88% beat Palvella Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Palvella Therapeutics N/A -56.87% -42.50% Spyre Therapeutics N/A -42.88% -27.76%

Does the media refer more to PVLA or SYRE?

In the previous week, Spyre Therapeutics had 4 more articles in the media than Palvella Therapeutics. MarketBeat recorded 11 mentions for Spyre Therapeutics and 7 mentions for Palvella Therapeutics. Palvella Therapeutics' average media sentiment score of 0.53 beat Spyre Therapeutics' score of 0.01 indicating that Palvella Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palvella Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spyre Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is COGT or PVLA more profitable?

Palvella Therapeutics' return on equity of -56.87% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cogent Biosciences N/A -104.27% -54.64% Palvella Therapeutics N/A -56.87% -42.50%

Does the media favor COGT or PVLA?

In the previous week, Palvella Therapeutics had 5 more articles in the media than Cogent Biosciences. MarketBeat recorded 7 mentions for Palvella Therapeutics and 2 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 0.68 beat Palvella Therapeutics' score of 0.53 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Palvella Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Palvella Therapeutics (PVLA) Competitors

$105.25 -3.42 (-3.15%)

Closing price 04:00 PM Eastern

Extended Trading

$105.24 -0.01 (-0.01%)

As of 04:10 PM Eastern

Compare

PVLA vs. LNTH, PTGX, RYTM, SYRE, and COGT

Should you buy Palvella Therapeutics stock or one of its competitors? MarketBeat compares Palvella Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Palvella Therapeutics include Lantheus (LNTH), Protagonist Therapeutics (PTGX), Rhythm Pharmaceuticals (RYTM), Spyre Therapeutics (SYRE), and Cogent Biosciences (COGT). These companies are all part of the "pharmaceutical products" industry.

How does Palvella Therapeutics compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Palvella Therapeutics (NASDAQ:PVLA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

99.1% of Lantheus shares are held by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are held by institutional investors. 1.7% of Lantheus shares are held by company insiders. Comparatively, 20.5% of Palvella Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Lantheus has higher revenue and earnings than Palvella Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.55B	4.21	$233.56M	$4.15	24.10
Palvella Therapeutics	$42.81M	35.26	-$41.72M	-$4.17	N/A

Lantheus has a beta of -0.03, indicating that its stock price is 103% less volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.14, indicating that its stock price is 114% less volatile than the broader market.

Lantheus has a net margin of 18.05% compared to Palvella Therapeutics' net margin of 0.00%. Lantheus' return on equity of 29.32% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Palvella Therapeutics	N/A	-56.87%	-42.50%

In the previous week, Palvella Therapeutics had 3 more articles in the media than Lantheus. MarketBeat recorded 7 mentions for Palvella Therapeutics and 4 mentions for Lantheus. Lantheus' average media sentiment score of 0.54 beat Palvella Therapeutics' score of 0.53 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Palvella Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus currently has a consensus price target of $101.86, suggesting a potential upside of 1.85%. Palvella Therapeutics has a consensus price target of $199.53, suggesting a potential upside of 89.58%. Given Palvella Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Palvella Therapeutics is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94

Summary

Lantheus beats Palvella Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Palvella Therapeutics compare to Protagonist Therapeutics?

Palvella Therapeutics (NASDAQ:PVLA) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Palvella Therapeutics has a net margin of 0.00% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-56.87%	-42.50%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

40.1% of Palvella Therapeutics shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 20.5% of Palvella Therapeutics shares are owned by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Palvella Therapeutics had 3 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 7 mentions for Palvella Therapeutics and 4 mentions for Protagonist Therapeutics. Palvella Therapeutics' average media sentiment score of 0.53 beat Protagonist Therapeutics' score of 0.43 indicating that Palvella Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palvella Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Palvella Therapeutics has a beta of -0.14, indicating that its share price is 114% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.85, indicating that its share price is 85% more volatile than the broader market.

Palvella Therapeutics presently has a consensus target price of $199.53, suggesting a potential upside of 89.58%. Protagonist Therapeutics has a consensus target price of $115.21, suggesting a potential upside of 17.53%. Given Palvella Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Palvella Therapeutics is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Palvella Therapeutics has higher earnings, but lower revenue than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Palvella Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palvella Therapeutics	$42.81M	35.26	-$41.72M	-$4.17	N/A
Protagonist Therapeutics	$74.06M	85.12	-$130.15M	-$1.81	N/A

Summary

Palvella Therapeutics beats Protagonist Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Palvella Therapeutics compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Palvella Therapeutics (NASDAQ:PVLA) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Palvella Therapeutics has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -93.33%. Palvella Therapeutics' return on equity of -56.87% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
Palvella Therapeutics	N/A	-56.87%	-42.50%

Rhythm Pharmaceuticals has a beta of 1.91, meaning that its share price is 91% more volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.14, meaning that its share price is 114% less volatile than the broader market.

40.1% of Palvella Therapeutics shares are held by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are held by insiders. Comparatively, 20.5% of Palvella Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Rhythm Pharmaceuticals currently has a consensus target price of $131.81, suggesting a potential upside of 53.40%. Palvella Therapeutics has a consensus target price of $199.53, suggesting a potential upside of 89.58%. Given Palvella Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Palvella Therapeutics is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94

Palvella Therapeutics has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Palvella Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$217.17M	27.12	-$196.54M	-$3.13	N/A
Palvella Therapeutics	$42.81M	35.26	-$41.72M	-$4.17	N/A

In the previous week, Palvella Therapeutics had 4 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 7 mentions for Palvella Therapeutics and 3 mentions for Rhythm Pharmaceuticals. Palvella Therapeutics' average media sentiment score of 0.53 beat Rhythm Pharmaceuticals' score of 0.00 indicating that Palvella Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Palvella Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Palvella Therapeutics beats Rhythm Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

How does Palvella Therapeutics compare to Spyre Therapeutics?

Palvella Therapeutics (NASDAQ:PVLA) and Spyre Therapeutics (NASDAQ:SYRE) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

In the previous week, Spyre Therapeutics had 4 more articles in the media than Palvella Therapeutics. MarketBeat recorded 11 mentions for Spyre Therapeutics and 7 mentions for Palvella Therapeutics. Palvella Therapeutics' average media sentiment score of 0.53 beat Spyre Therapeutics' score of 0.01 indicating that Palvella Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palvella Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spyre Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

40.1% of Palvella Therapeutics shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 20.5% of Palvella Therapeutics shares are owned by company insiders. Comparatively, 15.7% of Spyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Spyre Therapeutics' return on equity of -42.88% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-56.87%	-42.50%
Spyre Therapeutics	N/A	-42.88%	-27.76%

Palvella Therapeutics has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Palvella Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palvella Therapeutics	$42.81M	35.26	-$41.72M	-$4.17	N/A
Spyre Therapeutics	N/A	N/A	-$155.20M	-$2.08	N/A

Palvella Therapeutics currently has a consensus price target of $199.53, indicating a potential upside of 89.58%. Spyre Therapeutics has a consensus price target of $91.33, indicating a potential upside of 26.85%. Given Palvella Therapeutics' higher probable upside, research analysts clearly believe Palvella Therapeutics is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Palvella Therapeutics has a beta of -0.14, indicating that its stock price is 114% less volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.05, indicating that its stock price is 205% more volatile than the broader market.

Summary

Spyre Therapeutics beats Palvella Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Palvella Therapeutics compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Palvella Therapeutics (NASDAQ:PVLA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Cogent Biosciences presently has a consensus target price of $43.73, suggesting a potential upside of 40.33%. Palvella Therapeutics has a consensus target price of $199.53, suggesting a potential upside of 89.58%. Given Palvella Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Palvella Therapeutics is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94

Palvella Therapeutics' return on equity of -56.87% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Palvella Therapeutics	N/A	-56.87%	-42.50%

Palvella Therapeutics has higher revenue and earnings than Cogent Biosciences. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Palvella Therapeutics	$42.81M	35.26	-$41.72M	-$4.17	N/A

40.1% of Palvella Therapeutics shares are owned by institutional investors. 6.6% of Cogent Biosciences shares are owned by insiders. Comparatively, 20.5% of Palvella Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Cogent Biosciences has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.14, meaning that its stock price is 114% less volatile than the broader market.

In the previous week, Palvella Therapeutics had 5 more articles in the media than Cogent Biosciences. MarketBeat recorded 7 mentions for Palvella Therapeutics and 2 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 0.68 beat Palvella Therapeutics' score of 0.53 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Palvella Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Palvella Therapeutics beats Cogent Biosciences on 10 of the 15 factors compared between the two stocks.

Get Palvella Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PVLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PVLA vs. The Competition

Export

Metric	Palvella Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.51B	$3.30B	$6.43B	$12.05B
Dividend Yield	N/A	2.31%	2.67%	5.56%
P/E Ratio	-25.24	18.93	23.75	23.75
Price / Sales	35.26	176.22	479.79	84.65
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	44.60	8.04	10.28	6.78
Net Income	-$41.72M	$23.89M	$3.57B	$337.51M
7 Day Performance	-6.52%	-6.04%	-1.45%	-2.72%
1 Month Performance	-13.22%	2.72%	3.25%	1.87%
1 Year Performance	314.37%	36.16%	23.34%	26.60%

Palvella Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PVLA Palvella Therapeutics	2.9506 of 5 stars	$105.25 -3.1%	$199.53 +89.6%	+327.8%	$1.51B	$42.81M	N/A	N/A	Positive News
LNTH Lantheus	2.1715 of 5 stars	$99.86 +0.8%	$101.86 +2.0%	+23.8%	$6.50B	$1.54B	24.04	1,193
PTGX Protagonist Therapeutics	2.1525 of 5 stars	$100.07 -2.1%	$115.21 +15.1%	+79.1%	$6.45B	$46.02M	N/A	120
RYTM Rhythm Pharmaceuticals	2.177 of 5 stars	$93.00 +1.7%	$131.81 +41.7%	+26.9%	$6.37B	$189.76M	N/A	140
SYRE Spyre Therapeutics	2.4842 of 5 stars	$72.67 +0.2%	$90.25 +24.2%	+334.0%	$6.29B	$890K	N/A	73	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PVLA) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Palvella Therapeutics (PVLA) Competitors

PVLA vs. LNTH, PTGX, RYTM, SYRE, and COGT

How does Palvella Therapeutics compare to Lantheus?

Summary

How does Palvella Therapeutics compare to Protagonist Therapeutics?

Summary

How does Palvella Therapeutics compare to Rhythm Pharmaceuticals?

Summary

How does Palvella Therapeutics compare to Spyre Therapeutics?

Summary

How does Palvella Therapeutics compare to Cogent Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVLA vs. The Competition

Palvella Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Palvella Therapeutics (PVLA) Competitors

PVLA vs. LNTH, PTGX, RYTM, SYRE, and COGT

How does Palvella Therapeutics compare to Lantheus?

Do insiders & institutionals hold more shares of LNTH or PVLA?

Which has higher earnings and valuation, LNTH or PVLA?

Which has more risk & volatility, LNTH or PVLA?

Is LNTH or PVLA more profitable?

Does the media refer more to LNTH or PVLA?

Do analysts prefer LNTH or PVLA?

Summary

How does Palvella Therapeutics compare to Protagonist Therapeutics?

Is PVLA or PTGX more profitable?

Do institutionals & insiders hold more shares of PVLA or PTGX?

Does the media prefer PVLA or PTGX?

Which has more volatility & risk, PVLA or PTGX?

Do analysts recommend PVLA or PTGX?

Which has better valuation and earnings, PVLA or PTGX?

Summary

How does Palvella Therapeutics compare to Rhythm Pharmaceuticals?

Is RYTM or PVLA more profitable?

Which has more risk and volatility, RYTM or PVLA?

Do insiders and institutionals believe in RYTM or PVLA?

Do analysts prefer RYTM or PVLA?

Which has stronger earnings & valuation, RYTM or PVLA?

Does the media favor RYTM or PVLA?

Summary

How does Palvella Therapeutics compare to Spyre Therapeutics?

Does the media refer more to PVLA or SYRE?

Do institutionals and insiders have more ownership in PVLA or SYRE?

Is PVLA or SYRE more profitable?

Which has better valuation and earnings, PVLA or SYRE?

Do analysts rate PVLA or SYRE?

Which has more risk & volatility, PVLA or SYRE?

Summary

How does Palvella Therapeutics compare to Cogent Biosciences?

Do analysts recommend COGT or PVLA?

Is COGT or PVLA more profitable?

Which has higher valuation and earnings, COGT or PVLA?

Do institutionals and insiders hold more shares of COGT or PVLA?

Which has more risk & volatility, COGT or PVLA?

Does the media favor COGT or PVLA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVLA vs. The Competition

Palvella Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools